NCT00976248View on ClinicalTrials.gov

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2018

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

RAD001

Taken orally once a day

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER